Profilnine
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Profilnine
- Generic name
- FACTOR IX COMPLEX
- Manufacturer
- GRIFOLS USA, LLC
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- 79821042-86a5-4a64-b621-76de0a0bbab2
- SPL ID
- d13b6d66-7106-4a34-8521-1cf16d2578b9
- Version
- 33
- Effective date
- 2026-04-01
- Source export date
- 2026-11-13
- Source partition
- 12
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0012-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/df974ce21ba33b4471866e2af5412327fbd4bcd68d14b42d7cfb3aa15d163738/drug-label-0012-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:55:16
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 102476 | derived:openfda.application_number |
| application number | BLA102476 | openfda.application_number | |
| brand name | Profilnine | openfda.brand_name | |
| generic name | FACTOR IX COMPLEX | openfda.generic_name | |
| manufacturer name | GRIFOLS USA, LLC | openfda.manufacturer_name | |
| ndc | package | 76297-002-02 | openfda.package_ndc |
| ndc | package | 68516-1002-2 | openfda.package_ndc |
| ndc | package | 68516-3207-1 | openfda.package_ndc |
| ndc | package | 76297-002-12 | openfda.package_ndc |
| ndc | package | 68516-3208-2 | openfda.package_ndc |
| ndc | package | 68516-3206-2 | openfda.package_ndc |
| ndc | package | 68516-3211-2 | openfda.package_ndc |
| ndc | package | 68516-1001-1 | openfda.package_ndc |
| ndc | package | 68516-3212-2 | openfda.package_ndc |
| ndc | package | 68516-3209-2 | openfda.package_ndc |
| ndc | package | 68516-3210-1 | openfda.package_ndc |
| ndc | package | 68516-3205-2 | openfda.package_ndc |
| ndc | package | 68516-3204-1 | openfda.package_ndc |
| ndc | product | 68516-3212 | openfda.product_ndc |
| ndc | product | 68516-3211 | openfda.product_ndc |
| ndc | product | 68516-3208 | openfda.product_ndc |
| ndc | product | 68516-3210 | openfda.product_ndc |
| ndc | product | 68516-3207 | openfda.product_ndc |
| ndc | product | 68516-3209 | openfda.product_ndc |
| ndc11 | package | 68516320602 | derived:openfda.package_ndc |
| ndc11 | package | 68516320802 | derived:openfda.package_ndc |
| ndc11 | package | 76297000212 | derived:openfda.package_ndc |
| ndc11 | package | 76297000202 | derived:openfda.package_ndc |
| ndc11 | package | 68516100101 | derived:openfda.package_ndc |
| ndc11 | package | 68516320701 | derived:openfda.package_ndc |
| ndc11 | package | 68516320502 | derived:openfda.package_ndc |
| ndc11 | package | 68516321102 | derived:openfda.package_ndc |
| ndc11 | package | 68516321202 | derived:openfda.package_ndc |
| ndc11 | package | 68516100202 | derived:openfda.package_ndc |
| ndc11 | package | 68516320902 | derived:openfda.package_ndc |
| ndc11 | package | 68516321001 | derived:openfda.package_ndc |
| ndc11 | package | 68516320401 | derived:openfda.package_ndc |
| rxcui | 1670387 | openfda.rxcui | |
| rxcui | 1670392 | openfda.rxcui | |
| spl id | d13b6d66-7106-4a34-8521-1cf16d2578b9 | id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS Transmissible Infectious Agents Because Profilnine is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. Inhibitors Patients can develop neutralizing antibodies (inhibitors) after treatment with Profilnine. Monitor patients for inhibitors, which should be quantified in Bethesda Units (BU) using appropriate laboratory testing. Hypersensitivity Hypersensitivity, including anaphylaxis, has been reported. Inform patients of the early symptoms and signs of hypersensitivity reaction, including hives, generalized urticaria, angioedema, chest tightness, dyspnea, wheezing, faintness, hypotension, tachycardia, and anaphylaxis. Thrombosis The use of factor IX complex concentrates has been associated with the development of thromboembolic complications. Patients at increased risk for thrombosis include those undergoing surgery, post surgery, with known liver disease, and with signs of fibrinolysis , thrombosis, or disseminated intravascular coagulation (DIC) 5 . When administering Profilnine to these high-risk patients, monitor for early signs of consumptive coagulopathy with appropriate laboratory testing. Only administer Profilnine to patients when the benefits outweigh the risks.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS Adverse reactions with Profilnine may include headache, fever, chills, flushing, nausea, vomiting, tingling, lethargy, urticaria, and manifestations of allergic reactions. The following adverse reactions have been identified during post-approval use of Profilnine: hypersensitivity reactions including shortness of breath, diaphoresis, and hypotension, as well as thrombosis including pulmonary embolism and deep vein thrombosis, disseminated intravascular coagulation, and inhibitor development. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. To report SUSPECTED ADVERSE REACTIONS, contact Grifols at 1-888-GRIFOLS (1-888-474-3657) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.